Pitavastin 4mg — Competitive Intelligence Brief

Pitavastin 4mg (Pitavastin 4mg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statins. Area: Metabolic.

marketed Statins HMG-CoA reductase Metabolic Small molecule

Target snapshot

Pitavastin 4mg (Pitavastin 4mg) — University of Kansas Medical Center.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pitavastin 4mg TARGET	Pitavastin 4mg	University of Kansas Medical Center	marketed	Statins	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
simvastatin and ezetimibe	simvastatin and ezetimibe	UMC Utrecht	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase and NPC1L1 transporter
High dose potent statin	High dose potent statin	University of Florida	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2037-06-07 — Lipitor · 11654106 · US
• 2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (Statins class)

1. Oriental Neurosurgery Evidence-Based-Study Team · 1 drug in this class
2. Samsung Medical Center · 1 drug in this class
3. University of Kansas Medical Center · 1 drug in this class